Am J Transplant, Volume 18, Suppl 3 Archives - Page 185 of 211 - ATC Abstracts

2018 American Transplant Congress
Impact of Rapid Discontinuation of Prednisone on Kidney Transplant Outcomes in At-Risk Subpopulations: An OPTN/SRTR Analysis
D. Vock,¹ A. Matas.²
¹Public Health, U of MN, Mpls, MN; ²Surgery, U of MN, Mpls, MN.
Objective: Successful RDP (rapid discontinuation of prednisone <1 week post-tx) after kidney transplant (KTx) has been reported for low-risk populations. We studied the impact of…
2018 American Transplant Congress
Early Considerations for Deceased Donor Chains
A. Toll,¹ R. Leishman,¹ V. Casingal,² M. Aeder,³ T. Sandholm,⁴ N. Turgeon.⁵
¹UNOS, Richmond, VA; ²Carolinas HeathCare Sys, Charlotte, NC; ³Univ Hosp Med Ctr, Cleveland, OH; ⁴Carnegie Mellon Univ, Pittsburgh, PA; ⁵Emory Univ, Atlanta, GA.
Background: The potential use of deceased kidney donors (DDs) to initiate kidney paired donation (KPD) chains (DD chains) has been of interest to the transplant…
2018 American Transplant Congress
Comparison of Recipients with Early and Late Presenting Polyomavirus Nephropathy (PVN) with Regard to Histological Findings and Graft Survival: What is the Influence of CD4/CD8 Ratio on the Presenting Time of PVN
B. Ozdemir,¹ S. Ayva,¹ A. Terzi,¹ A. Ok Atilgan,¹ E. Akcay,¹ E. Ayvazoglu Soy,² F. Ozdemir,³ M. Haberal.²
¹Pathology, Baskent University, Ankara, Turkey; ²Transplantation, Baskent University, Ankara, Turkey; ³Nephrology, Baskent University, Ankara, Turkey.
Introduction: PVN is a common complication occurring around 12 mo after renal transplant (RT). We aimed to explore the differences between early and late-onset PVN…
2018 American Transplant Congress
Pancreas Transplant Recipients with End-Stage Renal Disease Benefit from Kidney Transplantation
Y. Tang, Z. Zhu, S. Huang, Z. Zhang, W. Ju, Z. Guo, X. He, G. Chen.
Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Background: End-stage renal disease (ESRD) has been shown after pancreas transplant alone (PTA), however, the benefit of kidney transplantation (KT) in PTA recipients with ESRD…
2018 American Transplant Congress
Shared HLA Specificities between the Blood and Transplant Donor Increases the Risk of De Novo DSA Development Following Blood Transfusion in Transplant Recipients
S. Hassan,¹ F. Regan,² C. Brown,³ A. Harmer,² N. Anderson,² E. Santos,⁴ P. Brookes,⁴ D. Taube,¹ M. Willicombe.¹
¹Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, United Kingdom; ²Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom; ³Histocompatibility and Immunogenetics, NHS Blood and Transplant, London, United Kingdom; ⁴Histocompatibility and Immunogenetics, Imperial College Healthcare NHS Trust, London, United Kingdom.
Introduction: Blood transfusions post-transplant have been shown to be associated with the development of de novo DSA and inferior allograft outcomes. The mechanisms behind this…
2018 American Transplant Congress
HLA Eplet Mismatch and Donor Specific Antibodies in Kidney Transplantation
S. Wan,^1,2 S. Angel de Wilde,² B. Rosales,² S. Chadban,^1,2 K. Wyburn.^1,2
¹Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ²Sydney Medical School, University of Sydney, Sydney, Australia.
BACKGROUND: Although HLA matching improves graft survival in kidney transplant recipients (KTx), eplet mismatches provide higher resolution information, and could better predict the development of…
2018 American Transplant Congress
Emergence of a Costimulation-Susceptible T Cell Repertoire Post-Alemtuzumab Induction
Q. Gao,¹ A. Mehta,² A. Guasch,² L. Stempora,¹ A. Kirk,¹ H. Xu.¹
¹Department of Surgery, Duke University Medical Center, Durham, NC; ²Emory Transplant Center, Emory University School of Medicine, Atlanta, GA.
Kidney transplant patients treated with belatacept-based regimens without depletional induction have higher rates of costimulation blockade resistant rejection (CoBRR). In contrast, belatacept effectively prevents rejection…
2018 American Transplant Congress
Improving Prognostication amongst Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma: An International, 16-Center Study to Validate and Recalibrate HALTHCC
D. Firl,¹ K. Sasaki,¹ S. Kimura,² W. Dumronggittigule,³ A. Gorgen,⁴ J. Lerut,⁵ M. Rossi,⁶ U. Cillo,⁷ A. Viveiros,⁸ E. Tsochatzis,⁹ G. Otto,¹⁰ G. Ettorre,¹¹ G. Tisone,¹² M. Vivarelli,¹³ S. Agnes,¹⁴ J. Markmann,² T. Ikegami,¹⁵ T. Kaido,¹⁶ G. Sapisochin,⁴ V. Agopian,³ Q. Lai,^5,6 F. Aucejo.¹
¹CCF, Cleveland; ²MGH, Boston; ³UCLA, LA; ⁴UHN, Toronto, Canada; ⁵SLH, Louvain, Belgium; ⁶UH, Rome, Italy; ⁷UP, Padua, Italy; ⁸MUI, Innsbruck, Austria; ⁹UCL, London, United Kingdom; ¹⁰UM, Mainz, Germany; ¹¹SCH, Rome, Italy; ¹²TVU, Rome, Italy; ¹³AOU, Torrette Ancona, Italy; ¹⁴AGH, Rome, Italy; ¹⁵KU, Kyoto, Japan; ¹⁶KU, Kyushu, Japan.
Objective: Prognosticating outcomes in liver transplant (LT) for hepatocellular carcinoma (HCC) continues to challenge the field. Whereas adoption of the binary Milan Criteria (MC) generalized…
2018 American Transplant Congress
Mechanisms of DEPTOR Function in CD4⁺ T Cell Subsets
J. Wedel,¹ K. Liu,¹ P. Sage,² M. Laplante,³ D. Briscoe.¹
¹Transplant Research Program, Boston Children's Hospital, Harvard Medical School, Boston; ²Department of Microbiology and Immunobiology, Harvard Medical School, Boston; ³IUCP, Lavel University, Quebec, Canada.
We have previously observed that the cell intrinsic modulatory protein DEPTOR (DEP) stabilizes Foxp3 expression, enhances Treg function and inhibits Treg dedifferentiation. In vivo, sustained…
2018 American Transplant Congress
Liver Transplantation Outcomes after Share 35: Analysis of NASH Recipients from UNOS Database
Y. Zhang,¹ M. Boktour.²
¹Department of Biostatistics, University of Texas Health Science Center, Houston, TX; ²Department of Surgery, Methodist Hospital, Houston, TX.
Background: Non-alcoholic steatohepatitis (NASH) is a rapidly growing indication for liver transplantation (LT) among patients with end-stage liver diseases. The study aimed to examine the…